Medical Patent News

RSS

PDL, UCB enter definitive settlement agreement to resolve all legal patent disputes

UCB SA, on behalf of its affiliate UCB Pharma S.A., and PDL BioPharma, today jointly announced that the companies have entered into a definitive settlement agreement that resolves all legal disputes between them, including those relating to UCB's pegylated humanized antibody fragment, Cimzia, and PDL's patents known as the Queen et al. patents.

8 Feb 2011

USPTO issues key patent to ISTO's NuQu product for degenerative disc disease treatment

ISTO Technologies, Inc. announced today that the United States Patent and Trademark Office has granted the company a key patent covering the primary technology for ISTO's NuQu product.

7 Feb 2011

AMS files patent lawsuit against BI in Colorado's Federal District Court

Denver-based Alcohol Monitoring Systems filed suit today in Colorado's Federal District Court asserting that Boulder-based BI Incorporated, a pending acquisition of The GEO Group, has infringed multiple patents with their BI TAD system. The GEO Group is one of the nation's largest operators of correctional facilities.

5 Feb 2011

U.S. Patent Office issues Notice of Allowance to Antigen Express AE37 cancer vaccine

Generex Biotechnology Corporation, together with its wholly-owned immunotherapeutic vaccines subsidiary, Antigen Express, announced today that Antigen Express has received a Notice of Allowance from the United States Patent Office relating to an application making augmentative pharmaceutical composition claims for the Antigen Express AE37 immunotherapeutic cancer vaccine.

4 Feb 2011

Acacia subsidiary acquires rights to prescription lens technology patent portfolio

Acacia Research Corporation announced today that a subsidiary has acquired rights to a patent portfolio for prescription lens technology.

3 Feb 2011

USPTO issues notice of allowance to Vermillion's breast cancer biomarkers

Vermillion, a molecular diagnostics company, today announced that the United States Patent and Trademark Office has issued a notice of allowance for a patent entitled "Biomarkers for breast cancer" to the Company.

2 Feb 2011

USPTO Board of Patent Appeals rules in favor of Pacific Biosciences in case against Life Technologies

Pacific Biosciences of California, Inc. today announced that the Board of Patent Appeals and Interferences of the United States Patent and Trademark Office (USPTO) has rendered a decision in a previously announced patent interference provoked by Pacific Biosciences related to single molecule sequencing. The decision cancels all patent claims by Life Technologies Corporation involved in the interference.

1 Feb 2011

BIO President comments on introduction of Patent Reform Act of 2011

Biotechnology Industry Organization President and CEO Jim Greenwood released the following comment on the introduction of the Patent Reform Act of 2011 (S. 23) by Senate Judiciary Committee Chairman Patrick Leahy (D-VT) earlier this week

29 Jan 2011

Neuralstem ends litigation with ReNeuron

Neuralstem, Inc. announced that it has reach a settlement with ReNeuron, Ltd. ending litigation between the parties.

28 Jan 2011

Lipocine files new patent applications in support of oral testosterone product for hypogonadism

Lipocine Inc. announced today that in addition to its issued patents involving oral testosterone, it has recently filed two new patent applications in support of its oral testosterone product for hypogonadism, also known as low testosterone (low T). These applications cover Lipocine's novel oral testosterone product (LPCN 1021) being developed to overcome the issues with currently marketed topical, parenteral, and transdermal testosterone products.

28 Jan 2011

USPTO issues Notice of Allowances to Lakewood's three patent applications for treatment of HUS

Lakewood-Amedex, a leading developer of novel anti-infective pharmaceuticals, announced today that the United States Patent and Trademark Office has issued Notice of Allowances on three patent applications relating to the use of novel monoclonal antibodies for the treatment of hemolytic uremic syndrome caused by shiga toxin II secreting E.coli O157: H7 strain.

28 Jan 2011

BDSI refutes MonoSol's patent infringement claims relating to BEMA Buprenorphine

BioDelivery Sciences International, Inc. today responded to a process patent infringement lawsuit filed and recently served against the Company and certain co-defendants by MonoSol Rx, LLC. The purpose in responding at this time is for BDSI to strongly refute MonoSol's claims and to assure BDSI stockholders that the Company remains focused on vigorously progressing its pipeline and not allowing this claim to present a distraction.

24 Jan 2011

Repligen enters exclusive license agreement with UCI for use of HDAC3 inhibitors for memory disorders

Repligen Corporation announced today that it has entered into an exclusive license agreement with the University of California, Irvine (UCI) for a patent application covering the use of histone deacetylase 3 (HDAC3) inhibitors for the treatment of disorders involving preservation or extinction of memory including Alzheimer's disease, memory impairment and post traumatic stress disorder.

21 Jan 2011

Novo Nordisk to appeal against ruling in repaglinide combination patent case

Today, Novo Nordisk announced that Judge Avern Cohn of the US District Court for the Eastern District of Michigan issued an adverse ruling in a patent litigation case regarding Novo Nordisk's US Patent No. 6,677,358. The district court ruled that the patent, which covers the combination use of repaglinide and metformin for the treatment of type 2 diabetes, is invalid and unenforceable.

From Novo Nordisk 20 Jan 2011

USPTO grants KL4 surfactant combination product patent to Discovery Labs

Discovery Laboratories, Inc. has been notified that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent Number 7,863,241 titled "Compositions for Treatment and Prevention of Pulmonary Conditions." The patent provides broad coverage for compositions that employ a combination of certain pulmonary surfactants with a broad array of protease inhibitors, administered as either a liquid or aerosol, for treating pulmonary inflammation.

19 Jan 2011

National Jewish Health issued method patent for desensitizing B cells

National Jewish Health has been issued a US patent claiming a method to desensitize B cells by inactivating antigen receptors on their surfaces. The method, discovered by John Cambier, PhD, Chairman of the Integrated Department of Immunology at National Jewish Health, holds promise for treatment of B-cell mediated diseases, such as lymphoma and leukemia, rheumatoid arthritis, lupus and rejection of organ transplants.

19 Jan 2011

Aastrom secures US patent for autologous cell therapy product

Aastrom Biosciences, a leading developer of expanded autologous cellular therapies for severe, chronic cardiovascular diseases, today announced that it has been granted a U.S. patent which provides composition of matter protection for its investigational expanded autologous cell therapy product.

19 Jan 2011

Seordus recieves Japanese patent for SER100

The Norwegian cardiovascular biopharmaceutical company Seordus AS today announced that the Japanese Patent Office has granted a patent for Japan covering Serodus' proprietary product SER100, an ORL-1 receptor agonist, which Serodus intends to develop for patients with isolated systolic hypertension.

18 Jan 2011

Vitrolife receives patent protection for Swemed Sense needle in European markets

Swemed Sense™ is a unique needle that is used for the collection of oocytes in connection with IVF. The approved patent means that Vitrolife has both design protection and product patent protection for Swemed Sense™ in strategically important European markets. A patent has also been applied for in other prioritized markets.

14 Jan 2011

Kenneth D. Steinsapir receives rare USPTO patent for Microdroplet BOTOX

Kenneth D. Steinsapir, M.D., has been issued a rare patent (US 7,846,457 B2) by The United States Patent and Trademark Office for the invention of a breakthrough method for administering cosmetic botulinum toxin. The patent for Microdroplet botulinum toxin, a nonsurgical cosmetic facial treatment that improves upon standard BOTOX treatments, was officially approved on December 7, 2010.

13 Jan 2011

Medical Patent News

PDL, UCB enter definitive settlement agreement to resolve all legal patent disputes

USPTO issues key patent to ISTO's NuQu product for degenerative disc disease treatment

AMS files patent lawsuit against BI in Colorado's Federal District Court

U.S. Patent Office issues Notice of Allowance to Antigen Express AE37 cancer vaccine

Acacia subsidiary acquires rights to prescription lens technology patent portfolio

USPTO issues notice of allowance to Vermillion's breast cancer biomarkers

USPTO Board of Patent Appeals rules in favor of Pacific Biosciences in case against Life Technologies

BIO President comments on introduction of Patent Reform Act of 2011

Neuralstem ends litigation with ReNeuron

Lipocine files new patent applications in support of oral testosterone product for hypogonadism

USPTO issues Notice of Allowances to Lakewood's three patent applications for treatment of HUS

BDSI refutes MonoSol's patent infringement claims relating to BEMA Buprenorphine

Repligen enters exclusive license agreement with UCI for use of HDAC3 inhibitors for memory disorders

Novo Nordisk to appeal against ruling in repaglinide combination patent case

USPTO grants KL4 surfactant combination product patent to Discovery Labs

National Jewish Health issued method patent for desensitizing B cells

Aastrom secures US patent for autologous cell therapy product

Seordus recieves Japanese patent for SER100

Vitrolife receives patent protection for Swemed Sense needle in European markets

Kenneth D. Steinsapir receives rare USPTO patent for Microdroplet BOTOX

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News